Summary of study ST000578

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000384. The data can be accessed directly via it's Project DOI: 10.21228/M8DP41 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST000578
Study TitleExperiment HuA: Metabolomics of plasma samples from humans infected with Plasmodium vivax strain.
Study TypeLongitudinal study and treatment of multiple individuals with Chloroquine
Study SummaryPatients with vivax malaria were enrolled in this study from June 2011 to December 2012 at the Fundacão de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), an infectious disease referral center located in Manaus, Western Brazilian Amazon. This study, which required a 42-day follow-up period, was approved by the FMT-HVD Institutional Review Board and the Brazilian National Ethics Committee (CONEP) (IRB approval #: CAAE: 12516713.8.0000.0005). All protocols and documentation were reviewed and sample shipments approved by the Emory IRB. Male and female patients were eligible for inclusion if aged 6 months to 60 years, bodyweight >=5 kg, presenting a blood parasite density from 250 to 100,000 parasites/microliter and axillary temperature >=37.5°C or history of fever in the last 48 hours. Exclusion criteria were: use of antimalarials in the previous 30 days, refusal to be followed up for 42 days and any clinical complication. Patients received supervised treatment with 25 mg/kg of chloroquine (CQ) phosphate over a 3-day period (10 mg/kg on day 0 and 7.5 mg/kg on days 1 and 2). Primaquine (0.5 mg/kg per day for 7 days) was prescribed at the end of the 42-day follow-up period. Patients who vomited the first dose within 30 minutes after drug ingestion were re-treated with the same dose. Patients were evaluated on days 0, 1, 2, 3, 7, 14, 28 and 42 and, if they felt ill, at any time during the study period. Blood smear readings, complete blood counts, and diagnostic polymerase chain reaction (PCR) amplifications were performed at all time points. Three aliquots of 100 µL of whole blood from the day of a recurrence were spotted onto filter paper for later analysis by high performance liquid chromatography (HPLC) to estimate the levels of CQ and desethylchloroquine (DCQ) as previously described. In this study, CQ-resistance with parasitological failure was defined as parasite recurrence in the presence of plasma concentrations of CQ and DSQ higher than 100 ng/mL and microsatellite analysis revealing the presence of the same clonal nature at diagnosis and recurrence. The CQ-sensitive control group consisted of patients with no parasitemia recurring during follow-up period. A group of 20 healthy individuals from Brazil was used as non-malarial control group. Within the MaHPIC, this project is known as ‘Experiment HuA’. This dataset was produced by Dean Jones at Emory University.
Emory University
DepartmentSchool of Medicine, Vaccine Center at Yerkes
Last NameGalinksi
First NameMary
AddressEmory University, Yerkes National Primate Research Center, 954 Gatewood Rd, Room 003, Atlanta, GA 30329
Submit Date2017-02-20
Num Groups273
Total Subjects220
Raw Data AvailableYes
Raw Data File Type(s).raw,.cdf
Analysis Type DetailLC-MS
Release Date2017-07-10
Release Version1
Mary Galinksi Mary Galinksi application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000384
Project DOI:doi: 10.21228/M8DP41
Project Title:The Malaria Host-Pathogen Interaction Center (MaHPIC)
Project Type:Systems Biology
Project Summary:The Malaria Host-Pathogen Interaction Center (MaHPIC) is a transdisciplinary malaria systems biology research program supported by an NIH/NIAID contract (# HHSN272201200031C; see The MaHPIC generates many data types (e.g., metabolomics, functional genomics, lipidomics, proteomics, clinical, parasitological, immune response) and mathematical models, to iteratively test and develop hypotheses related to the complex host-parasite dynamics in the course of malaria in non-human primates, and metabolomics data via collaborations with investigators conducting clinical studies in malaria endemic countries, with the overarching goal of better understanding human disease, pathogenesis, and immunity. Curation and maintenance of all data and metadata are the responsibility of the MaHPIC: Mary Galinski (MaHPIC Program Director), Jessica Kissinger (MaHPIC Co-Program Director), Alberto Moreno (MaHPIC Co-Program Director), and Ebru Karpuzoglu (MaHPIC Scientific Project Manager)
Institute:Emory University
Department:School of Medicine, Vaccine Center at Yerkes
Last Name:Galinski
First Name:Mary
Address:Emory University, 954 Gatewood Rd, Atlanta, GA 30329
Funding Source:NIAID Contract: # HHSN272201200031C